Frequent Epigenetic Inactivation of Spleen Tyrosine Kinase Gene in Human Hepatocellular Carcinoma

Purpose: The aim of present study was to investigate the methylation and expression status of spleen tyrosine kinase (SYK) in human hepatocellular carcinoma (HCC) and to evaluate this information for its ability to predict disease prognosis. E-cadherin and TIMP-3 methylation was also analyzed here as control because both were associated with poor prognosis in some types of tumors. Experimental Design: We analyzed the methylation status of SYK, E-cadherin, and TIMP-3 in 124 cases of HCC and assessed the correlation of such methylations with clinicopathologic variables and prognosis after tumor resection. Results: We found that SYK, E-cadherin, and TIMP-3 genes were methylated in 27%, 27%, and 42% of HCC neoplastic tissues, respectively. The loss of SYK mRNA or Syk protein expression was highly correlated with SYK gene methylation. The patients with methylated SYK in neoplastic tissues had a significantly lower overall survival rate after hepatectomy than those with unmethylated SYK. No significant difference in overall survival rates, however, was found between groups of patients with methylated and unmethylated E-cadherin or TIMP-3. Patients with negative Syk protein expression had a significantly lower overall survival rate than those with positive Syk protein expression. Multivariate analyses indicated that factors affecting overall survival were tumor-node-metastasis stage, Child-Pugh classification, SYK methylation, or Syk protein status. Conclusions: Our results indicate that SYK methylation and loss of Syk expression in HCC neoplastic tissues are independent biomarkers of poor patient outcome and that determination of SYK methylation or Syk expression status may offer guidance for selecting appropriate treatments.

[1]  A. Sahin,et al.  Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness , 2005, International journal of cancer.

[2]  H. Pehamberger,et al.  The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells. , 2005, The Journal of investigative dermatology.

[3]  H. El‐Serag,et al.  Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.

[4]  J. Herman,et al.  E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. , 1995, Cancer research.

[5]  M. Buendia,et al.  Altered expression of E‐cadherin in hepatocellular carcinoma: Correlations with genetic alterations, β‐catenin expression, and clinical features , 2002, Hepatology.

[6]  J. Minna,et al.  Aberrant promoter methylation of multiple genes in non-small cell lung cancers. , 2001, Cancer research.

[7]  J. Vauthey,et al.  Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. , 1995, American journal of surgery.

[8]  W. Lau,et al.  A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. , 2005, Journal of the National Cancer Institute.

[9]  S. Thorgeirsson,et al.  Molecular pathogenesis of human hepatocellular carcinoma , 2002, Nature Genetics.

[10]  Li Zhang,et al.  Progressive Loss of Syk and Abnormal Proliferation in Breast Cancer Cells , 2004, Cancer Research.

[11]  J. Herman,et al.  Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. , 1999, Cancer research.

[12]  C. Wild,et al.  Tissue inhibitor of metalloproteinase‐3 (TIMP‐3) gene is methylated in the development of esophageal adenocarcinoma: Loss of expression correlates with poor prognosis , 2005, International journal of cancer.

[13]  J. Issa,et al.  Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications , 2001, Annals of Internal Medicine.

[14]  Masakazu Yamamoto,et al.  Favorable Surgical Outcomes in Patients With Early Hepatocellular Carcinoma , 2004, Annals of surgery.

[15]  Nita Ahuja,et al.  DNA methylation and environmental exposures in human hepatocellular carcinoma. , 2002, Journal of the National Cancer Institute.

[16]  Hyeon Joo Lee,et al.  Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. , 2003, The American journal of pathology.

[17]  M. Magnani,et al.  Prognostic Analysis of E-Cadherin Gene Promoter Hypermethylation in Patients with Surgically Resected, Node-Positive, Diffuse Gastric Cancer , 2004, Clinical Cancer Research.

[18]  S. McLeskey,et al.  The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells , 2000, Nature.

[19]  A. Hall,et al.  Primary prevention of hepatocellular carcinoma in developing countries. , 2000, Mutation research.

[20]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[21]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[22]  Hiromu Suzuki,et al.  Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 σ gene in human hepatocellular carcinoma , 2000, Oncogene.

[23]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[24]  J. Geschwind,et al.  The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Loda,et al.  Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  F. Uckun,et al.  Hypermethylation of the spleen tyrosine kinase promoter in T-lineage acute lymphoblastic leukemia , 2003, Oncogene.

[27]  S. Fan,et al.  Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Kent-Man Chu,et al.  Hepatic Resection for Hepatocellular Carcinoma An Audit of 343 Patients , 1995, Annals of surgery.

[29]  M. Feitelson,et al.  Genetic mechanisms of hepatocarcinogenesis , 2002, Oncogene.

[30]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. Sugioka,et al.  Hepatic resection for hepatocellular carcinoma. , 1990, Surgery.

[32]  A. Sahin,et al.  Hypermethylation leads to silencing of the SYK gene in human breast cancer. , 2001, Cancer research.

[33]  Jorge Cortes,et al.  Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. , 2004, Blood.

[34]  J. Herman,et al.  E-cadherin expression is silenced by 5' CpG island methylation in acute leukemia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  G. Kundu,et al.  Syk, a Protein-tyrosine Kinase, Suppresses the Cell Motility and Nuclear Factor κB-mediated Secretion of Urokinase Type Plasminogen Activator by Inhibiting the Phosphatidylinositol 3′-Kinase Activity in Breast Cancer Cells* , 2003, The Journal of Biological Chemistry.

[36]  Peter A. Jones,et al.  Continuous Zebularine Treatment Effectively Sustains Demethylation in Human Bladder Cancer Cells , 2004, Molecular and Cellular Biology.

[37]  S. Baylin,et al.  Aging and DNA methylation in colorectal mucosa and cancer. , 1998, Cancer research.

[38]  Hiroko Yamashita,et al.  Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer. , 2003, Cancer letters.

[39]  L. Ellis,et al.  Simplified staging for hepatocellular carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  J. Herman,et al.  Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. , 2003, Carcinogenesis.

[41]  C. Saccone,et al.  p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. , 1998, British Journal of Cancer.

[42]  David A Jones,et al.  Reactivating the expression of methylation silenced genes in human cancer , 2002, Oncogene.

[43]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[44]  J. Herman,et al.  Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. , 2003, The American journal of pathology.

[45]  D. Steinemann,et al.  Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma , 2003, Oncogene.

[46]  W. Symmans,et al.  Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. , 2003, Cancer research.

[47]  L. Ellis,et al.  Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. , 2001, Archives of surgery.